A pan-NADPH oxidase inhibitor
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

VAS2870

Item No. 19205

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
7-(2-benzoxazolylthio)-3-(phenylmethyl)-3H-1,2,3-triazolo[4,5-d]pyrimidine
CAS Number
722456-31-7
Molecular Formula
C18H12N6OS
Formula Weight
360.4
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 30 mg/mlDMF:PBS (pH 7.2) (1:3): 0.25 mg/mlDMSO: 25 mg/ml
λmax
284 nm
SMILES
C12=C(SC3=NC4=C(C=CC=C4)O3)N=CN=C1N(CC5=CC=CC=C5)N=N2
InChi Code
InChI=1S/C18H12N6OS/c1-2-6-12(7-3-1)10-24-16-15(22-23-24)17(20-11-19-16)26-18-21-13-8-4-5-9-14(13)25-18/h1-9,11H,10H2
InChi Key
HZSOKHVVANONPV-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $36

    Add

    5 mg

    $86

    Add

    10 mg

    $132

    Add

    25 mg

    $294

    Add
    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    VAS2870 is a selective inhibitor of the NADPH oxidases.1,2,3,4 Pre-incubation of rat vascular smooth muscle cells with VAS2870 abolishes platelet-derived growth factor-dependent chemotaxis without affecting cell cycle progression (IC50 = 10 µM).1 At low (2.8 mM), but not high (16.7 mM), concentrations of glucose, treatment with VAS2870 (20 µM) increases glucose-stimulated insulin secretion of rat pancreatic islets by 70%.5 It significantly reduces production of reactive oxygen species in mouse brain, rat vascular smooth muscle culture, and human umbilical vein endothelial cells.1,6,7 Treatment with VAS2870 pre- or post-ischemia is neuroprotective in mouse brain.6 VAS2870 inhibits vasculogenesis of mouse embryonic stem cell cultures and inhibits cell proliferation of rat hepatoma cells.8,9

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. ten Freyhaus, H., Huntgeburth, M., Wingler, K., et al. Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation. Cardiovasc. Res. 71(2), 331-341 (2006).

    2. Altenhöfer, S., Kleikers, P.W.M., Radermacher, K.A., et al. The NOX toolbox: validating the role of NADPH oxidases in physiology and disease. Cell. Mol. Life Sci. 69(14), 2327-2343 (2012).

    3. Wingler, K., Altenhofer, S.A., Kleikers, P.W.M., et al. VAS2870 is a pan-NADPH oxidase inhibitor. Cell. Mol. Life Sci. 69(18), 3159-3160 (2012).

    4. Wind, S., Beuerlein, K., Eucker, T., et al. Comparative pharmacology of chemically distinct NADPH oxidase inhibitors. Br. J. Pharmacol. 161(4), 885-898 (2010).

    5. Munhoz, A.C., Riva, P., Simões, D., et al. Control of insulin secretion by production of reactive oxygen species: Study performed in pancreatic islets from fed and 48-hour fasted Wistar rats. PLoS One 11(6), e0158166 (2016).

    6. Kleinschnitz, C., Grund, H., Wingler, K., et al. Post-stroke inhibition of induced NADPH oxidase type 4 prevents oxidative stress and neurodegeneration. PLoS One 8(9), e1000479 (2010).

    7. Stielow, C., Catar, R.A., Muller, G., et al. Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells. Biochem. Biophys. Res. Commun. 344(1), 200-205 (2006).

    8. Lange, S., Heger, J., Euler, G., et al. Platelet-derived growth factor BB stimulates vasculogenesis of embryonic stem cell-derived endothelial cells by calcium-mediated generation of reactive oxygen species. Cardiovasc. Res. 81(1), 159-168 (2009).

    9. Sancho, P., and Fabregat, I. The NADPH oxidase inhibitor VAS2870 impairs cell growth and enhances TGF-β-induced apoptosis of liver tumor cell. Biochem. Pharmacol. 81(7), 917-924 (2011).